EAM Global Investors’s Galectin Therapeutics GALT Stock Holding History

EAM Global Investors’s Portfolio GALT Stock Details GALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-164,511	Closed	-$1.05M	–	169
2018 Q2	$1.05M	Sell	164,511 -62,552	-28%	-$305K	0.51%	122
2018 Q1	$1.08M	Buy	+227,063	New	+$1.06M	0.56%	96

Other funds holding GALT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DADC

D.A. Davidson & Co Great Falls, Montana $18.1B AUM 24.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

FFA

First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return

BCA

Benchmark Capital Advisors New York $101M AUM 0.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

EAM Global Investors's GALT Position: Q3 2018 in Review

EAM Global Investors sold out of Galectin Therapeutics (GALT) in Q3 2018, closing a stake of 164,511 shares — an estimated $1.05M sold.

EAM Global Investors first reported a position in GALT in Q1 2018 and held it in 2 quarters. The position peaked at $1.08M in Q1 2018. 60 funds tracked by Wall St. Rank hold GALT as of Q3 2018.

EAM Global Investors reported no remaining Galectin Therapeutics position as of Q3 2018 after selling out during the quarter.
EAM Global Investors sold 164,511 Galectin Therapeutics shares in Q3 2018, an estimated $1.05M.
EAM Global Investors first reported a position in Galectin Therapeutics in Q1 2018 and held it in 2 quarters.
EAM Global Investors's Galectin Therapeutics position peaked at $1.08M in Q1 2018.
60 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q3 2018.

Based on EAM Global Investors's 13F filing for Q3 2018, filed 8 Nov 2018.